Insights into nanoparticle surface bonding and coating architecture via multinuclear NMR
- PMID: 40575764
- PMCID: PMC12199202
- DOI: 10.20935/acadnano7737
Insights into nanoparticle surface bonding and coating architecture via multinuclear NMR
Abstract
Tantalum oxide nanoparticles (TaOx NPs) are promising as high-Z-contrast agents for computed tomography (CT) due to their profound imaging benefits relative to those of clinical iodinated contrast media (ICM) at the X-ray tube voltages ≥100 kVp required for most patients. Furthermore, TaOx NPs have prevailed through extensive non-GLP and GLP (good laboratory practice) preclinical development, including in vivo/vitro safety testing and imaging efficacy studies. This is due in part to innovative structural engineering of the NPs' core size and coating, which has been shown to provide favorable pharmacokinetics and promote rapid renal clearance, with negligible organ retention. In this study, a carboxybetaine zwitterionic siloxane polymer (CZ) coating for a lead candidate TaOx NP is thoroughly characterized using multinuclear/multidimensional nuclear magnetic resonance (NMR) spectroscopic techniques. 1H and 1H/13C heteronuclear multiple bond correlation NMR spectroscopies are used to confirm the CZ coating's structure, and in combination with 29Si NMR, the architecture of the siloxane coating bound to the TaOx NPs' surface is described. Of particular significance, 29Si NMR spectra were used to identify the T-region bonding modes of the CZ coating and show the superiority of diafiltration over dialysis for purification of the TaOx NPs. Through a spectral comparison, a cyclic siloxane impurity in the TaOx NP product purified through dialysis was found to be absent in the product purified through diafiltration. Finally, the 1H Carr-Purcell-Meiboom-Gill (CPMG) NMR pulse sequence was used in a novel manner to probe the distance-dependent interactions between the 1H spins of the CZ coating and the TaOx NPs' surface.
Keywords: 29Si NMR; X-ray computed tomography; diagnostic imaging agent; nanoparticle; siloxane coating; tantalum oxide.
Conflict of interest statement
Conflict of interest B.M.Y. is a major shareholder of, consultant for, and on the Board of Directors for Nextrast, Inc; is a consultant for General Electric Healthcare; is a speaker for Philips Healthcare and General Electric Healthcare; receives royalties from Oxford University Press; and receives patent royalties from the University of California, San Francisco. The other authors declare no conflicts of interest.
Figures
References
-
- Erturk SM, Ros PR, Ichikawa T, Saylisoy S. Medical imaging contrast agents: a clinical manual. Cham: Springer; 2021. ISBN 978-3-030-79255-8.
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous